---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-215227"
form_type: "8-K"
ticker: "PBYI"
cik: "0001401667"
company_name: "PUMA BIOTECHNOLOGY, INC."
filed_at: "2021-07-14T23:59:59+00:00"
generated_at: "2026-06-30T05:21:51.417959+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Puma Biotechnology appoints Allison Dorval to board of directors

## Summary
- Appointment effective July 15, 2021; term expires at 2022 annual meeting.
- Dorval also appointed to the Audit Committee.
- Currently CFO of Voyager Therapeutics (since Nov 2018); CPA with life sciences background.
- Will receive standard non-employee director compensation and indemnification agreement.

## SEC filing metadata
- accession: 0001193125-21-215227
- form_type: 8-K
- ticker: PBYI
- cik: 0001401667
- company_name: PUMA BIOTECHNOLOGY, INC.
- filed_at: 2021-07-14T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401667/000119312521215227/0001193125-21-215227-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401667/000119312521215227/d119549d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-215227
- JSON: https://secwatch.observer/filing/0001193125-21-215227.json
- Plain text: https://secwatch.observer/filing/0001193125-21-215227.txt

## Key facts
- Executive change
  Allison Dorval was appointed as Director at PUMA BIOTECHNOLOGY, INC..
  - Action: appointed
  - Role: Director
  source text: On July 8, 2021, Allison Dorval, 45, was appointed to the Board of Directors (the “Board”) of Puma Biotechnology, Inc. (the “Company”), effective July 15, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1401667/000119312521215227/0001193125-21-215227-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.